Clinical Trials Browser

Phase 2 × INDUSTRY × parsaclisib × Clear all

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase 2 Active not recruiting

112 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT02998476 2025-08-22

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Phase 2 Completed

60 enrolled 15 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03144674 2025-07-11

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Phase 2 Completed

110 enrolled 18 charts

Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT03235544 2025-03-18

(CITADEL-205)

Phase 2 Completed

162 enrolled 18 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03126019 2025-03-14

CITADEL-203

Phase 2 Completed

126 enrolled 15 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies

NCT04434937 2024-10-23

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Phase 2 Completed

42 enrolled 13 charts

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT04298879 2024-06-05

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Phase 2 Completed

81 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase 2 Terminated

74 enrolled 40 charts

Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis